

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
17 August 2006 (17.08.2006)

PCT

(10) International Publication Number
WO 2006/084917 A1

(51) International Patent Classification:
C07D 471/04 (2006.01) **A61P 29/00** (2006.01)
A61K 31/551 (2006.01)

N.V. Organon, P.O. Box 20, NL-5340 BH Oss (NL).
BUIJSMAN, Rogier, Christian [NL/NL]; N.V. Organon, P.O. Box 20, NL-5340 BH Oss (NL). **MAN, Adrianus, Petrus, Antonius** [NL/NL]; N.V. Organon, P.O. Box 20, NL-5340 BH Oss (NL). **CONTI, Paolo, Giovanni, Martino** [IT/NL]; N.V. Organon, P.O. Box 20, NL-5340 BH Oss (NL). **LUSHER, Scott, James** [GB/NL]; N.V. Organon, P.O. Box 20, NL-5340 BH Oss (NL). **DOKTER, Willem, Hendrik, Abraham** [NL/NL]; N.V. Organon, P.O. Box 20, NL-5340 BH Oss (NL).

(21) International Application Number:
PCT/EP2006/050906

(22) International Filing Date:
14 February 2006 (14.02.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
05101086.6 14 February 2005 (14.02.2005) EP

(71) Applicant (for all designated States except US): **AKZO NOBEL N.V.** [NL/NL]; Velperweg 76, NL-6824 BM Arnhem (NL).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **PLATE, Ralf** [DE/NL]; N.V. Organon, P.O. Box 20, NL-5340 BH Oss (NL). **ZAMAN, Guido, Jenny, Rudolf** [NL/NL]; N.V. Organon, P.O. Box 20, NL-5340 BH Oss (NL). **HERMKENS, Pedro, Harold, Han** [NL/NL]; N.V. Organon, P.O. Box 20, NL-5340 BH Oss (NL). **JANS, Christiaan, Gerardus, Johannes, Maria** [NL/NL];

(74) Agent: **VAN WEZENBEEK, P., M., G., F.**; P.O. Box 20, NL-5340 BH Oss (NL).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,

[Continued on next page]

(54) Title: NON STEROIDAL GLUCOCORTICOID RECEPTOR MODULATORS

(I)



(57) Abstract: The present invention relates to compounds having general Formula (I) or a pharmaceutically acceptable salt thereof. In this formula R₁ is H or (1-4C)alkyl; R₂ is -C(O)R₁₅ or -S(O)2R₁₅; R₃ is H, (1-4C)alkyl or -OR₁₆; R₄ is H, (1-4C)alkyl or -OR₁₆; R₆ is H or -C(H)NOR₁₆; R₇ is H or halogen, cyano; (1-6C)alkyl, (2-6C)alkenyl or (2-6C)alkynyl, all three optionally substituted with OH, halogen or NH₂; -C(H)NOR₁₆, -OR₁₆, -C(O)R₁₆, or -C(O)OR₁₆; R₈ is H, cyano, halogen, nitro; (1-6C) alkyl, (2-6C)alkenyl, (2-6C)alkynyl or -O(1-6C)alkyl, all optionally substituted with amino, hydroxyl or halogen; (hetero)aryl, optionally substituted with cyano, halogen, (1-4C)alkyl, (1-4C)alkoxy, (1-4C)alkoxy(1-4C)alkyl, -C(O)R₁₈, -C(O)OR₁₉, -C(O)NHR₁₇, -NHC(O)R₂₀, -C(1-4C)alkylNOR₂₁; -C(H)NOR₁₆, or -NHS(O)₂R₂₁; R₉ is H, halogen, cyano or (1-4C)alkyl optionally substituted with halogen; R₁₀ is H or (1-4C)alkyl; R₁₁ is H; R₁₂ is H, cyano or (1-4C)alkyl; R₁₃ is H, (1-4C)alkyl, halogen or formyl; R₁₄ is H, halogen, cyano, (1-4C)alkyl, (2-6C)alkenyl, C(O)R₂₁ or (hetero)aryl; R₁₅ is H; (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, -O(2-6C)alkyl, -O(2-6C)alkenyl or -O(2-6C)alkynyl, all optionally substituted with one or more OH, halogen, cyano or (hetero)aryl, (hetero)aryl, optionally substituted with (1-4C)alkyl, halogen, cyano, nitro or amino, NH₂, (di)(1-4C)alkylamino, (1-4C)alkyl(1-4C)alkoxyamine, (1-4C)alkyl(hi(1-4C)alkyl or (1-4C)alkoxy(1-4C)alkyl; R₁₆ is H, (1-6C)alkyl, (2-6C)alkenyl or (2-6C)alkynyl; R₁₇ is H, (1-6C)alkyl, optionally substituted with halogen, (1-4C)alkoxy or (hetero)aryl, optionally substituted with halogen, (1-4C)alkyl or (1-25 4C)alkoxy; (3-6C)cycloalkyl or (hetero)aryl, optionally substituted with halogen, (1-4C)alkyl or halogen, (1-4C)alkoxy; R₁₈ is H, NH₂, C(O)R₂₁ or (1-4C)alkyl, optionally substituted with OH, halogen, cyano or -S(1-4C)alkyl; R₁₉ is H or (1-6C)alkyl, optionally substituted with OH or halogen; R₂₀ is H, (1-6C)alkyl or (2-6C)alkenyl, both optionally substituted by halogen, O(1-6C)alkyl, (hetero)aryl, optionally substituted with (1-4C)alkyl or halogen; (3-6C)cycloalkyl; (1-6C)alkoxy; (1-6C)alkenyloxy; or (hetero)aryl, optionally substituted with (1-4C)alkyl; NH₂, -NH(1-6C)alkyl or -NH(hetero)aryl and R₂₁ is H or (1-6C)alkyl. The present invention also relates to pharmaceutical compositions comprising said compounds and the use of these derivatives to modulate glucocorticoid receptor activity.

WO 2006/084917 A1



ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

— *with international search report*

Non steroid glucocorticoid receptor modulators

The present invention relates to glucocorticoid receptor modulating compounds as well as to the use of these compounds in therapy.

5

Intracellular receptors are a class of structurally related proteins involved in the regulation of gene proteins. Steroid receptors are a subset of these receptors, including the glucocorticoid receptor (GR), progesterone receptor (PR), androgen receptor (AR), estrogen receptor (ER), and mineralocorticoid receptor (MR). Regulation of a gene by 10 such receptors or factors requires the intracellular receptor and a corresponding ligand which has the ability to selectively bind to the receptor in a way that affects gene transcription.

The current steroid glucocorticoid receptor modulators (glucocorticoids) like prednisolone a.o. are very effective anti-inflammatory agents that are currently used in 15 over 100 indications in the fields of Rheumatology, Hematology, Pulmology, Dermatology, Gastro-enterology, Endocrinology, Neurology, and Nephrology. Indications treated include Rheumatoid Arthritis (RA), Inflammatory Bowel Disease (IBD), Lupus, allergies, asthma, psoriasis and many others (J.D. Baxter, Advances in Internal Medicine 45; 317-349; 2000). Anti-inflammatory effects of these compounds 20 are thought to be mediated through an inhibition of the expression of pro-inflammatory mediators like adhesion molecules, cytokines, chemokines and enzymes by a mechanism that involves the interaction of the ligand-bound GR with transcription factors. This mechanism is referred to as transrepression (M. Karin, Cell 93;487-490; 1998).

25


The use of current steroid glucocorticoids is accompanied by metabolic and other side effects (e.g. diabetes, hypertension, osteoporosis, muscle wasting, a.o.). Part of these side effects are thought to be mediated through the direct interaction of the ligand bound GR to glucocorticoid responsive elements (GRE's) on the DNA of target genes 30 and the subsequent induction of gene expression (J.D. Baxter, Advances in Internal Medicine 45; 317-349; 2000; M. Karin, Cell 93;487-490; 1998). Another part of these side effects might be due to cross-reactivity with other steroid receptors, like the mineralcorticoid (MR) or the progesterone receptor (PR).

- 2 -

Non-steroidal glucocorticoids have no molecular structural similarity with steroids and therefore one might also expect differences in physicochemical properties, pharmacokinetics (PK) parameters, tissue distribution (*e.g.* CNS versus peripheral) and more importantly non-steroidal glucocorticoids may show no/less cross-reactivity to other steroid receptors or may show no/less metabolic or other side effects.

The present invention provides non-steroidal compounds that modulate glucocorticoid receptor activity. More particularly, the present invention provides high affinity non-steroidal compounds for GR binding which show anti-inflammatory effects *in vitro* and *in vivo*. According to the present invention compounds are provided having a general formula I, or a prodrug thereof, or a pharmaceutically acceptable salt thereof.

The present invention provides non-steroidal compounds that modulate glucocorticoid receptor activity. More particularly, the present invention provides high affinity non-steroidal compounds which are agonists, partial agonists or antagonists of the glucocorticoid receptor. According to the present invention compounds are provided having a general formula I,



20

Formula I

or a pharmaceutically acceptable salt thereof.

In this Formula, the R groups have the following meanings:

R₁ is H or (1-4C)alkyl;

R₂ is -C(O)R₁₅ or -S(O)₂R₁₅

25 R₃ is H, (1-4C)alkyl or -OR₁₆

R₄ is H, (1-4C)alkyl or -OR₁₆

R₆ is H or -C(H)NOR₁₆;

- R₇ is H or halogen, cyano;
(1-6C)alkyl, (2-6C)alkenyl or (2-6C)alkynyl, all three optionally substituted with OH, halogen or NH₂ ;
-C(H)NOR₁₆, -OR₁₆, -C(O)R₁₆, or -C(O)OR₁₆;
- 5 R₈ is H, cyano, halogen, nitro;
(1-6C) alkyl, (2-6C)alkenyl, (2-6C)alkynyl or -O(1-6C)alkyl, all optionally substituted with amino, hydroxyl or halogen;
(hetero)aryl, optionally substituted with cyano, halogen, (1-4C)alkyl, (1-4C)alkoxy, (1-4C)alkoxy(1-4C)alkyl;
- 10 -C(H)NOR₁₆, -C(O)NHR₁₇, -C(O)R₁₈, -C(O)OR₁₉, -NHC(O)R₂₀, -NHS(O)₂R₂₁; or -C(1-4C)alkylNOR₂₁;
- R₉ is H, halogen, cyano or (1-4C)alkyl optionally substituted with halogen;
R₁₀ is H or (1-4C)alkyl;
- R₁₁ is H;
- 15 R₁₂ is H, cyano or (1-4C)alkyl;
R₁₃ is H, (1-4C)alkyl, halogen or formyl;
R₁₄ is H, halogen, cyano, (1-4C)alkyl, (2-6C)alkenyl, C(O)R₂₁ or (hetero)aryl;
R₁₅ is H;
(1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, -O(2-6C)alkyl, -O(2-6C)alkenyl or -O(2-6C)alkynyl, all optionally substituted with one or more OH, halogen, cyano or (hetero)aryl,
- 20 (hetero)aryl, optionally substituted with (1-4C)alkyl, halogen, cyano, nitro or amino NH₂, (di)(1-4C)alkylamino, (1-4C)alkyl(1-4C)alkoxyamine, (1-4C)alkylthio(1-4C)alkyl or (1-4C)alkoxy(1-4C)alkyl;
- 25 R₁₆ is H, (1-6C)alkyl, (2-6C)alkenyl or (2-6C)alkynyl;
R₁₇ is H,
(1-6C)alkyl, optionally substituted with halogen, (1-4C)alkoxy or (hetero)aryl, optionally substituted with halogen, (1-4C)alkyl or (1-4C)alkoxy;
(3-6C)cycloalkyl or
- 30 (hetero)aryl, optionally substituted with halogen, (1-4C)alkyl or (1-4C)alkoxy;
R₁₈ is H, NH₂, -C(O)R₂₁ or (1-4C)alkyl, optionally substituted with OH, halogen, cyano or -S(1-4C)alkyl;
- R₁₉ is H or (1-6C)alkyl, optionally substituted with OH or halogen;
R₂₀ is H,
- 35 (1-6C)alkyl or (2-6C)alkenyl, both optionally substituted by halogen, O(1-6C)alkyl, (hetero)aryl, optionally substituted with (1-4C)alkyl or halogen;
(3-6C)cycloalkyl; (1-6C)alkoxy; (1-6C)alkenyloxy; or

(hetero)aryl, optionally substituted with (1-4C)alkyl), NH₂, -NH(1-6C)alkyl or -NH(hetero)aryl;
and
R₂₁ is H or (1-6C)alkyl;

5

Thus, it has now been found, that the foregoing class of compounds according to Formula I or pharmaceutically acceptable salts thereof, have glucocorticoid receptor modulatory activity.

- 10 The term (1-6C)alkyl as used in the definition of the invention means a branched or unbranched alkyl group having 1-6 carbon atoms, for example methyl, ethyl, propyl, isopropyl, butyl, sec-butyl and tert-butyl, pentyl and hexyl. Preferred are (1-4C)alkyl.
The term (1-4C)alkyl as used in the definition of the invention means a branched or unbranched alkyl group having 1-4 carbon atoms, for example methyl, ethyl, propyl,
15 isopropyl, butyl, sec-butyl and tert-butyl. Preferred are methyl and ethyl. Most preferred is methyl.

The term (3-6C)cycloalkyl means a cyclic alkyl group having 3-6 carbon atoms.

The term halogen means fluorine, chlorine, bromine or iodine.

- 20 The term (2-6C)alkenyl means a branched or unbranched alkenyl group having 2-6 carbon atoms, such as ethenyl, 2-butenyl, pentenyl and hexenyl. Preferred are (2-4C)alkenyl.

The term (2-4C)alkenyl means a branched or unbranched alkenyl group having 2-4 carbon atoms, such as ethenyl and 2-butenyl.

- 25 The term (2-6C)alkynyl means a branched or unbranched alkynyl group having 2-6 carbon atoms, such as ethynyl, propynyl, butylyn, pentynyl and hexynyl. Preferred are (2-4C)alkynyl.

The term (2-4C)alkynyl means a branched or unbranched alkynyl group having 2-4 carbon atoms, such as ethynyl and propynyl.

- 30 The term -O(1-6C)alkyl means (1-6C)alkyloxy wherein (1-6C)alkyl has the previously defined meaning.

The term -O(2-6C)alkenyl means (2-6C)alkenyloxy wherein (2-6C)alkenyl has the previously defined meaning.

The term -O(2-6C)alkynyl means (2-6C)alkynyloxy wherein (2-6C)alkynyl has the previously defined meaning.

The term (1-4C)alkyloxy means an alkyloxy group having 1-4 carbon atoms, the alkyl moiety having the same meaning as previously defined. (1-2C)Alkyloxy groups are 5 preferred.

The term (1-4C)alkoxy(1-4C)alkyl means a (1-4C)alkoxy attached to a (1-4C)alkyl group, both groups having the previously defined meanings.

The term (di)(1-4C)alkylamino means a amino moiety, with at least one, optionally two hydrogens replaced by a (1-4C) alkyl group as previously defined.

10 The term -S(1-4C)alkyl means a (1-4C)alkylthio group, the (1-4C)alkyl group having the previously identified meaning.

The term (1-4C)alkylthio(1-4C)alkyl means an (1-4C)alkylthio group attached to a (1-4C)alkyl group, both having the previously defined meanings.

The term aryl means 6 membered aromatic ring system.

15 The term heteroaryl means a 5 or 6 membered aromatic ring system containing at least one heteroatom selected from the group of N, O and S in a 5 membered ring and N in a 6 membered ring, such as pyridyl, pyrimidyl, tetrazolyl or thiadiazolyl.

The term (hetero)aryl means aryl or heteroaryl as defined above.

20 The term pharmaceutically acceptable salt represents those salts which are, within the scope of medical judgement, suitable for use in contact for the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio. Pharmaceutically acceptable salts are well known in the art. They may be obtained during the final isolation and purification of the compounds of the invention, or separately by reacting the free base function with a suitable mineral acid such as hydrochloric acid, phosphoric acid, or sulfuric acid, or with an organic acid such as for example ascorbic acid, citric acid, tartaric acid, lactic acid, maleic acid, malonic acid, fumaric acid, glycolic acid, succinic acid, propionic acid, acetic acid, methanesulfonic acid, and the like. The acid function can be reacted with an organic or a mineral base, like sodium hydroxide, potassium 25 hydroxide or lithium hydroxide.

30

The compounds of the present invention possess at least two chiral carbon atoms and may therefore be obtained as pure enantiomers, or as a mixture of enantiomers, or as a mixture of diastereomers. Methods for obtaining the pure enantiomers are known in the art, *e.g.* crystallization of salts which are obtained from optically active acids and the 5 racemic mixture, or chromatography using chiral columns. For separation of diastereomers, straight phase or reversed phase columns may be used.

The invention also relates to compounds according to Formula I wherein R₇ is H, halogen or -OR₁₆.

- 10 The invention also relates to compounds according to Formula I wherein R₂ is C(O)R₁₅.

In yet another aspect the invention relates to compounds according to Formula I wherein R₇ is H.

The invention further relates to those compounds wherein R₁₀ in Formula I is methyl.

- 15 The invention also relates to those compounds wherein R₄ in Formula I is H or (1-4C)alkyl.

Another aspect of the invention concerns compounds according to Formula I wherein R₁₆ is H or (1-6C)alkyl.

In another aspect the invention relates to compounds wherein R₁₄ is (1-4C)alkyl.

- 20 In yet another aspect the invention relates to compounds wherein R₁₅ is (1-4C)alkyl optionally substituted with halogen, cyano, nitro or amino.

In yet another aspect the invention relates to compounds wherein R₁₅ is (1-4C)alkyl optionally substituted with halogen.

In yet another aspect the invention relates to compounds of Formula I wherein R₁₅ is trifluoromethyl or (hetero)aryl, optionally substituted with (1-4C)alkyl.

- 25 The invention also relates to compounds of Formula I wherein R₁₅ is (hetero)aryl, optionally substituted with (1-4C)alkyl.

In a further aspect R₂₁ in the compounds according to Formula I is (1-4C)alkyl.

The invention also relates to compounds according to Formula I wherein R₈ is H, halogen, cyano, nitro, -C(O)R₁₈, -NHC(O)R₂₀ or (hetero)aryl, optionally substituted with cyano, (1-4C)alkyl, (1-4C)alkoxy, (1-4C)alkoxy(1-4C)alkyl or (hetero)aryl).

The invention also relates to compounds according to Formula I wherein R₈ is H,
5 halogen, cyano, nitro, -C(O)R₁₈, -NHC(O)R₂₀ or (hetero)aryl, optionally substituted with cyano, (1-4C)alkyl, (1-4C)alkoxy or (1-4C)alkoxy(1-4C)alkyl.

The invention furthermore relates to those compounds wherein R₈ is H, cyano, pyridyl or nitro.

In another aspect the invention relates to compounds wherein R₈ is cyano, pyridyl or
10 nitro. The invention also relates to compounds wherein R₈ is cyano.

In still another aspect the invention relates to compounds according to Formula I wherein R₁, R₃, R₄, R₆, R₇, R₉, R₁₁, R₁₂, R₁₃ and R₁₄ are H.

Yet another aspect of the invention concerns compounds wherein all specific definitions of the groups R₁ through R₂₁ as defined here above are combined in the
15 compound of formula I.

The invention also resides in compounds according to Formula I which are highly specific for the glucocorticoid receptor. Specificity can be determined by testing the compound as described further on for the glucocorticoid receptor, with other well-known receptors such as progesterone receptor, androgen receptor, mineralocorticoid receptor or estrogen receptor.
20

Synthesis:


25 The sequence of steps to synthesize the compounds of the present invention are described in Scheme 1.

The compounds of the present invention can be prepared by first coupling 2-halonitroaryls of general structure 1, in which X has the meaning previously defined for halogens, with (N-alkyl)aniline derivatives.

- 8 -

The above mentioned reaction is typically conducted at elevated temperature in the presence of potassium carbonate and with, or without, the use of an organic solvent. 2-halonitroaryls of general structure **1** are either commercially available or easily accessible via synthetic routes, which are well documented in the literature. This
5 reaction is reported in the literature by G.W. Rewcastle, et. al. J. Med. Chem., 30, 1987, 843. Alternatively, these reactions can be carried out in the presence of caesium carbonate, palladium acetate and BINAP to afford an analogous product.

Scheme1



Compounds of general structure **2** can then be reduced to afford compounds of general structure **3**.

15 The above mentioned reaction is typically conducted at ambient temperature in the presence of tin(II)chloride with an organic solvent then treated with hydroxide.

Compounds of general structure **3** can then be N-formylated to afford compounds of general structure **4**.

The above mentioned reaction is typically conducted in refluxing formic acid, without the use of any organic solvent.

Compounds of general structure **4** can then be ring closed to form ring C and afford tricyclic compounds of general structure **5**.

- 5 The above mentioned reaction is typically conducted at ambient temperature in the presence of phosphorous pentachloride, with the use of an organic solvent. Alternatively, these reactions can be carried out in the presence of polyphosphoric acid and phosphorous (V) trichloride oxide, without the use of any organic solvent, to afford the desired product.
- 10 Compounds of general structure **5** can then be reacted in a Hetero-Diels-Alder fashion to form the piperine ring and afford the tetracyclic compounds. These compounds can then be reduced in-situ to afford the tetracyclic alcohols of general structure **6**, which are obtained mainly in the trans configuration.

The Diels-Alder reaction is typically conducted at reduced temperature in the presence
15 of either trimethyl[(1-methylene-2-propenyl)oxy]silane, trimethyl[(1-methylene-2-but enyl)oxy]silane, or [(3-methoxy-1-methylene-2-propenyl)oxy]trimethylsilane (Danishefsky's diene) and ytterbium trifluoromethanesulfonate, with the use of an organic solvent. These crude products can then be reduced at ambient temperature in the presence of sodium borohydride, with the use of an organic solvent.

- 20 Compounds of general structure **6** can then reacted under Mitsunobu conditions to afford azide compounds of general structure **7**.

The above mentioned reaction is typically conducted at ambient temperature in the presence of triphenylphosphine, diisopropylazodicarboxylate and diphenylphosphoryl azide, with the use of an organic solvent.

- 25 Compounds of general structure **7** can then be reduced to afford the free amine compounds of general structure **8**. This reaction is typically conducted at ambient temperature in the presence of triphenylphosphine and water, with the use of an organic solvent. These compounds can then be coupled by general procedures with carboxylic acid derivatives (acids, acid chlorides or esters) to afford the amide products **9**.

30

Compounds **6**, **8** and **9** are the key intermediate compounds in the formation of all other compounds disclosed within. Functionality of these key intermediates can be achieved by selection of the appropriate starting materials, or by halogenation, nitration, formylation, etc. and then further modified by the methods described within (e.g.

Buchwald, Suzuki, Stille, aromatic substitution, etc.) to afford the desired entities **9** with the desired cis stereochemistry.

The compounds of the present invention possess at least two stereogenic carbon atoms
5 and may therefore be obtained as pure enantiomers, as a mixture of enantiomers, or as a mixture of diastereoisomers. Generally these are isolated as a mixture of enantiomers. Diastereoisomers can be separated using straight phase or reversed phase chromatography. Methods for obtaining the pure enantiomers are well known in the art, e.g. chromatography using chiral columns.

10

Biological activity:

Methods to determine receptor binding as well as *in vitro* and *in vivo* assays to determine biological activity of the compounds are well known. In general, the expressed receptor is treated with the compound to be tested and binding, stimulation 15 or inhibition of a functional response is measured.

To measure binding, isolated cytosol containing the expressed GR may be used. Radioactive or fluorescence labelled compounds may also be used. As reference compound, native hormone or other compounds binding to the receptor can be used. As an alternative, also competition binding assays can be performed. These binding assays 20 can be either developed in house or might be purchased as commercially available binding assays (kits). Experimental methods to determine binding affinities are well known in the art.

For selecting GR modulators, compounds should bind with an affinity of $< 10^{-5}$ M to the receptor. More preferably, binding affinity is $< 10^{-7}$ M and most preferably, binding 25 affinity is $< 10^{-8}$ M.

To measure a functional response, isolated DNA encoding the glucocorticoid receptor gene, preferably the human receptor, is expressed in suitable host cells, for instance in human osteoblastic U2OS cells.

Methods to construct recombinant glucocorticoid receptor-expressing cell lines are 30 well known in the art. Expression of receptor is attained by expression of the DNA encoding the desired protein. Techniques for site directed mutagenesis, ligation of additional sequences, PCR and construction of suitable expression systems are all, by now, well known in the art. Portions or the entire DNA encoding the desired protein can be constructed synthetically using standard solid phase techniques, preferably to

include restriction sites for ease of ligation. Suitable control elements for transcription and translation of the included coding sequence can be provided to the DNA coding sequences. As is well known, expression systems are now available which are compatible with a wide variety of hosts, including prokaryotic hosts, such as bacteria,
5 and eukaryotic hosts, such as yeast, plant cells, insect cells, mammalian cells, avian cells and the like.

In vitro, inflammation can be mimicked in a human cell line, stably transfected with human GR DNA that is stimulated to secrete cytokines, chemokines and other inflammatory mediators. Anti-inflammatory effects of compounds can be quantified by
10 measuring inhibition of the inflammatory response in that cell line. By testing full dose response curves, EC₅₀ values can be calculated for both compounds and a reference compound like prednisolone. EC₅₀ values might be compared to the EC₅₀ values obtained for prednisolone within the same cellular assay. Preferably compounds have EC₅₀ values that are in the range of the EC₅₀ obtained for prednisolone. More
15 preferably, EC₅₀ values are less than that obtained for prednisolone.

The skilled artisan will recognize that desirable EC₅₀ values are dependent on the compound tested. For example, a compound with an EC₅₀, which is less than 10⁻⁵ M is, generally, considered a candidate for drug selection. Preferably this value is lower than 10⁻⁷ M. However, a compound which has a higher EC₅₀, but is selective for the
20 particular receptor, may be even a better candidate.

In vivo, the anti-inflammatory effect of compounds can be tested in mice that are treated with lipopolysaccharide (LPS). Compounds can be administered systemically at or before the time of LPS treatment. Anti-inflammatory effects can be quantified as an inhibition of LPS-induced TNF α in the serum of mice or any other inflammatory
25 cytokine or chemokine (S.R. Hyde & R.E. McCallum, *Infection and Immunity*, 60; 976-982 (1992)). The potency to inhibit arthritis could be tested in the mouse collagen type II-induced arthritis model (CIA) as the ability to inhibit paw swelling (D.E. Trentham et al. *J Exp Med* 146; 857-868 (1977)), or another arthritis model.

30 The invention thus also resides in a pharmaceutical composition comprising a compound or a salt thereof having the general formula I. Thus, the compounds according to formula I can be used in therapy.

Suitable administration routes for the compounds of formula I or pharmaceutically acceptable salts thereof, also referred to herein as the active ingredient are intramuscular injections, subcutaneous injections, intravenous injections or
35

intraperitoneal injections, oral and intranasal administration. Preferably, the compounds may be administered orally. The exact dose and regimen of administration of the active ingredient, or a pharmaceutical composition thereof, will necessarily be dependent upon the therapeutic effect to be achieved (e.g. treatment of asthma, R.A, 5 I.B.D) and may vary with the particular compound, the route of administration, and the age and condition of the individual subject to whom the medicament is to be administered. Generally, a therapeutically effective daily dose is from about 0.001 mg to about 15 mg/kg of body weight per day per compound of the invention; preferably, from about 0.1 mg to about 10 mg/kg of body weight per day; and most preferably, 10 from about 0.1 mg/kg to about 1.5 mg/kg of body weight per day. Some degree of routine dose optimization may be required to determine an optimal dosing level and pattern.

A further aspect of the invention resides in the use of the compounds according to Formula I or a pharmaceutically acceptable salt or solvate thereof for the preparation of 15 a medicament for all indications wherein the glucocorticoid receptor need to be modulated i.e. within the fields of Rheumatology, Hematology, Pulmology, Dermatology, Gastro-enterology, Endocrinology, Neurology or Nephrology that are currently treated with steroidal glucocorticoids like prednisolone. Most preferred is the field of Rheumatology, in particular e.g. rheumatoid arthritis.

- 20 The compounds of the present invention thus modulate glucocorticoid receptor activity and they can be used in the treatment of immunological and inflammatory diseases. In particular the compounds can be used to treat rheumatic diseases such as rheumatoid arthritis, juvenile arthritis, and ankylosing spondylitis, dermatological diseases including psoriasis and pemphigus, allergic disorders including allergic rhinitis, atopic 25 dermatitis, and contact dermatitis, pulmonary conditions including asthma and chronic obstructive pulmonary disease, and other immune and inflammatory diseases including Crohn disease, ulcerative colitis, systemic lupus erythematosus, autoimmune chronic active hepatitis, osteoarthritis, tendonitis, and bursitis. In addition, the compounds can be used to help prevent rejection of organs after organ transplantation.
- 30 More in particular the compounds can be used to treat rheumatoid arthritis, psoriasis, asthma and chronic obstructive pulmonary disease, Crohn disease or ulcerative colitis and the compounds can be used to help prevent rejection of organs after organ transplantation.

The compounds according to the invention can thus be used in the treatment of these diseases. i.e. all diseases wherein the patient is in need of modulating the glucocorticoid receptor.

5 Examples

Example 1

NB: The numbering in the examples refers to Scheme 1, where R₁,R₃,R₄,R₆-R₉ = H, R₁₀ = Me, R₁₁-R₁₄ = H, unless stated otherwise.

- Example 1,** cis-2,2,2-trifluoro-N-(8-formyl-1,2,3,4,10,14b-hexahydro-10-methyldi-
10 benzo[*b,f*]pyrido[1,2-*d*][1,4]diazepin-2-yl)acetamide (**9** : R₂ = C(O)CF₃; R₈ = CHO)
- A stirred solution of 2-bromonitrobenzene (**1**) (301 g, 1.5 mol) and N-methylaniline (176.5 g, 1.65 mol) in toluene (2.5 L) was degassed by bubbling through N₂ for 15 minutes. Caesium carbonate (537 g, 1.65 mol), Pd(OAc)₂ (973 mg, 4.3 mmol) and rac-BINAP (15.1 g, 24.3 mmol) were then added, with stirring, and the reaction was heated
15 to 85°C and held for 20 hours. Reaction was quenched with H₂O and the organics washed with 6M HCl, then H₂O and finally saturated brine then dried (Na₂SO₄). The organic layer was concentrated under reduced pressure and the crude product was purified by column chromatography on silica to afford (**2**) (341 g, 99 %). Data: (m/z) = 229 (M+H)⁺.
- 20 To a stirred solution of (**2**) (100 g, 0.5 mol) in ethanol (1 L) was added SnCl₂.2H₂O (451 g, 2.0 mol) and the mixture was stirred at ambient temperature overnight. The ethanolic solution was split into 4 portions and each was poured into 6M NaOH solution in H₂O (1 L). This was stirred until the solution discoloured then the product was extracted into EtOAc. The organic layers were combined and washed with
25 saturated brine then dried (Na₂SO₄). The organic layer was concentrated under reduced pressure and the crude product was purified by column chromatography on silica to afford (**3**) (78 g, 79 %). Data: (m/z) = 199 (M+H)⁺.

- A stirred solution of (**3**) (78 g, 0.39 mol) in formic acid (500 ml) was heated to reflux and held for 20 hours. The formic acid was removed under reduced pressure, and the
30 resulting oil was dissolved in EtOAc. The organics were washed with NaHCO₃ solution in H₂O then H₂O and finally saturated brine then dried (Na₂SO₄). The organics

were concentrated under reduced pressure and the crude product was purified by column chromatography on silica to afford (4) (61 g, 69 %). Data: (m/z) = 227 (M+H)⁺.

To a stirred solution of (4) (61 g, 270 mmol) in DCM (500 ml) PCl₅ (56.3 g, 270 mmol) was added portionwise. The reaction mixture was stirred for 1 hour at ambient temperature then poured into NaHCO₃ solution in H₂O (1 L). The pH of the reaction mixture was adjusted using solid NaHCO₃ until it was basic to litmus paper. The organic layer was separated and concentrated under reduced pressure. The resulting oil was dissolved in Et₂O. A 6M HCl solution in H₂O was then added and the system stirred for 30 minutes. The aqueous layer was separated, the organics washed twice with 6M HCl solution in H₂O. The aqueous fractions were combined and washed with Et₂O then neutralised. The product was extracted into EtOAc and washed with saturated brine, dried (Na₂SO₄) and concentrated under reduced pressure. The crude product was purified by column chromatography on silica to afford (5) (30 g, 54 %).

15 Data: (m/z) = 209 (M+H)⁺.

A stirred solution of (5) (30 g, 144 mmol) in toluene (350 ml) was cooled to 0°C then Danishefsky's diene (24.8 g, 144 mmol) and Yb(OTf)₃ (4.47 g, 7.2 mmol) were added. The solution was allowed to warm to ambient temperature and stir for 2 hours. The reaction was quenched with 0.1 M HCl in H₂O. Water was added and the product extracted into toluene. The organics were washed with saturated brine, dried (Na₂SO₄) then concentrated under reduced pressure to afford 10,14b-dihydro-10-methyl-dibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2(1H)one, (47 g, crude). This compound was suspended in ethanol (1 L) then NaBH₄ (21.8 g, 576 mmol) was added and the reaction mixture was stirred for 8 hours at ambient temperature. The organics were partly evaporated under reduced pressure and the resulting slurry was poured into saturated NH₄Cl solution in H₂O and the product was extracted into EtOAc. The organics were washed with saturated brine, dried (Na₂SO₄) and concentrated under reduced pressure. The crude product was purified by column chromatography on silica to afford (6) (23.4 g, 58 %). Data: (m/z) = 281 (M+H)⁺.

20 30 A stirred solution of (6) (10.0 g, 35.7 mmol) and triphenylphosphine (12.2 g, 46.4 mmol) in dry THF (150 ml) was cooled to 0°C and diisopropylazodicarboxylate (9.2 ml, 46.4 mmol) was added dropwise. Diphenylphosphorylazide (10.0 ml, 46.4 mmol)

was added dropwise, then the cooling was removed. The reaction was allowed to warm to ambient temperature and stirred for 2 hours. The reaction mixture was concentrated under reduced pressure and the crude product was purified by column chromatography on silica to afford (7) (13.1 g, 100 %). Data: (m/z) = 306 (M+H)⁺.

- 5 To a stirred solution of (7) (10.9 g, 35.7 mmol) and triphenylphosphine (13.4 g, 51.1 mmol) in THF (150 ml) was added H₂O (2 ml). The reaction mixture was stirred for 24 hours at ambient temperature then concentrated under reduced pressure to afford (8) (35 g, crude). Data: (m/z) = 280 (M+H)⁺.

The crude material of (8) was taken up in MeOH (400 ml), with stirring, then 10 triethylamine (19.4 ml, 140 mmol) and ethyltrifluoroacetate (20.9 ml, 175 mmol) were added and the reaction mixture was heated to 50°C and held for 3 hours. The reaction mixture was concentrated under reduced pressure then purified by column chromatography on silica to afford cis-2,2,2-trifluoro-N-(1,2,3,4,10,14b-hexahydro-10-methyldibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl)acetamide (9 : R₂ = COCF₃) (5.7 g, 15 58 % for two steps). Data: (m/z) = 376 (M+H)⁺.

Oxalyl chloride (436 µL, 5 mmol) was carefully added dropwise, with stirring, to DMF (0.5 ml) at 0°C then held for 25 minutes. A solution of cis-2,2,2-trifluoro-N-(1,2,3,4,10,14b-hexahydro-10-methyldibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl)acetamide (9 : R₂ = COCF₃) (400 mg, 1.07 mmol) in DMF (2 ml) was added dropwise to 20 the resulting suspension and the reaction mixture heated to 80°C and held for 1.5 hours. The reaction was cooled to ambient temperature and quenched by dropwise addition of NaHCO₃ solution in H₂O. The product was extracted into EtOAc, dried (Na₂SO₄) and concentrated under reduced pressure. Then the crude product was purified by column chromatography on silica to afford cis-2,2,2-trifluoro-N-(8-formyl-25 1,2,3,4,10,14b-hexahydro-10-methyldibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl)acetamide (9 : R₂ = COCF₃; R₈ = CHO) (130 mg, 30 %). Data: (m/z) = 404 (M+H)⁺. [Column chromatography also afforded cis-2,2,2-trifluoro-N-(6-formyl-1,2,3,4,10,14b-hexahydro-10-methyldibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl)acetamide (9 : R₂ = COCF₃; R₆ = CHO) (45 mg, 10 %). Data: (m/z) = 404 (M+H)⁺.]

Example 2, cis-2,2,2-trifluoro-N-(1,2,3,4,10,14b-hexahydro-10-methyl-8-nitrodibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl)acetamide (9 : R₂ = COCF₃; R₈ = NO₂)

A stirred solution of TFAA (188 μ L, 1.33 mmol) and TBAN (406 mg, 1.33 mmol) in DCM (5ml) was cooled to 0°C and stirred for 20 minutes then added dropwise to a 5 solution of (9 : R₂ = COCF₃) (250 mg, 0.67 mmol) in DCM (5 ml). The reaction mixture was stirred for 1.5 hours at 0°C then quenched (at 0°C) with NaHCO₃ solution in H₂O. The organics were separated and washed with H₂O then saturated brine, then were dried (PE-filter) and concentrated under reduced pressure. The crude product was purified by column chromatography on silica to afford cis-2,2,2-trifluoro-N- 10 (1,2,3,4,10,14b-hexahydro-10-methyl-8-nitrodibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl)acetamide (9 : R₂ = COCF₃; R₈ = NO₂) (110 mg, 42 %). Data: (m/z) = 421 (M+H)⁺.

Example 3, cis-N-(8-cyano-1,2,3,4,10,14b-hexahydro-10-methyldibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl)-2,2,2-trifluoroacetamide (9 : R₂ = COCF₃; R₈ = CN)

A stirred solution of (6) (12.7 g, 45.4 mmol) in acetone (175 ml) was cooled to 0°C and N-bromosuccinimide (10.4 g, 58.4 mmol) was added portionwise. The solution was allowed to warm to ambient temperature and stir for 3 hours. The reaction was then quenched with NaHCO₃ solution in H₂O and the product was extracted into EtOAc. 20 The organics were washed with saturated brine, dried (Na₂SO₄) and concentrated under reduced pressure. The crude product was purified by column chromatography on silica to afford (6 : R₈ = Br) (11.0 g, 67 %). Data: (m/z) = 360 (M+H)⁺.

(7 : R₈ = Br). This compound was prepared, in an analogous manner as described in Example 1 (vide infra). Product was not purified and thus carried through to next step 25 crude. Data: (m/z) = 385 (M+H)⁺.

(9 : R₂ = COCF₃; R₈ = Br) This compound was prepared, in an analogous manner as described in Example 1 (35 % for three steps). Data: (m/z) = 455 (M+H)⁺.

A solution of (9 : R₂ = COCF₃; R₈ = Br) (2 g, 4.4 mmol) and CuCN (1 g, 11 mmol) was degassed by bubbling nitrogen through for 0.5 hours. The reaction mixture was then 30 heated to 200°C and held for 4 hours, with stirring. The reaction was then quenched with NH₄OH solution in H₂O then filtered. The product was extracted into EtOAc and

the organics were washed with H₂O then dried (Na₂SO₄). The organics were concentrated under reduced pressure and the crude product purified by column chromatography on silica to afford cis-N-(8-cyano-1,2,3,4,10,14b-hexahydro-10-methyldibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl)-2,2,2-trifluoroacetamide (**9** : R₂ = COCF₃; R₈ = CN) (1.1 g, 62 %). Data: (m/z) = 401 (M+H)⁺.

Example 4, cis-1,2,3,4,10,14b-hexahydro-10-methyl-N-phenyl-2-(2,2,2-trifluoroacetylamino)dibenzo[b,f]pyrido[1,2-d][1,4]diazepine-8-carboxamide (**9** : R₂ = COCF₃; R₈ = C₇N₆NO)

10

To a stirred solution of cis-N-(8-cyano-1,2,3,4,10,14b-hexahydro-10-methyldibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl)-2,2,2-trifluoroacetamide (**9** : R₂ = COCF₃; R₈ = -CN) (900 mg, 2.25 mmol) in EtOH (50 ml) was added 6N KOH (20 ml). The reaction mixture was heated to 120°C and held for 1.5 hours using a microwave (120W).
15 The reaction mixture was cooled to ambient temperature and neutralised with 2M HCl in H₂O and the solvents removed by freeze-drying. The crude product was taken up in MeOH (50ml) then triethylamine (1.5ml, 10.8 mmol) and ethyl trifluoroacetate (1.4 ml, 11.7 mmol) were added. The reaction mixture was heated to 50°C and held for 3 hours then cooled to ambient temperature. The product was isolated by an acid-base
20 extraction and the organic layer was washed with H₂O, then saturated brine, then dried (Na₂SO₄) and concentrated under reduced pressure to afford crude (**9** : R₂ = COCF₃; R₈ = CO₂H) (737 mg, 78 % for 2 steps). Data: (m/z) = 420 (M+H)⁺.

To a stirred solution of (**9** : R₂ = COCF₃; R₈ = CO₂H) (30 mg, 0.72 mmol) in DMF (1 ml) was added TBTU (34.5 mg, 0.108 mmol) and DIPEA (68.3 µL, 0.360 mmol) and
25 the mixture was stirred for 10 minutes. Aniline (7.2 µL, 0.792 mmol) was then added and the reaction mixture was stirred at ambient temperature for 70 hours. The reaction was quenched with Na₂CO₃ solution in H₂O and the product was extracted into DCM. The organic layer was dried (Na₂SO₄) and concentrated under reduced pressure then the crude product was purified by column chromatography to afford cis-1,2,3,4,10,14b-
30 hexahydro-10-methyl-N-phenyl-2-(2,2,2-trifluoroacetylamino)dibenzo[b,f]pyrido[1,2-

d][1,4]diazepine-8-carboxamide (**9** : R₂ = COCF₃; R₈ = C₇H₆NO) (25 mg, 70 %). Data: (m/z) = 495 (M+H)⁺.

5 **Example 5**, cis-2,2-dichloro-N-(8-cyano-1,2,3,4,10,14b-hexahydro-10-methyldibenzo-[b,f]pyrido[1,2-*d*][1,4]diazepin-2-yl)acetamide (**9** : R₂ = COC_l₂; R₈ = CN)

To a stirred solution of cis-N-(8-cyano-1,2,3,4,10,14b-hexahydro-10-methyldibenzo-[b,f]pyrido[1,2-*d*][1,4]diazepin-2-yl)-2,2,2-trifluoroacetamide (**9** : R₂ = COCF₃; R₈ = CN) (900 mg, 2.25 mmol) in EtOH (50 ml) was added 2N NaOH (12 ml). The reaction
10 mixture was stirred at ambient temperature for 3 hours then the product was isolated by an acid-base extraction and the organic layer was washed with H₂O then saturated brine, then dried (Na₂SO₄) and concentrated under reduced pressure to afford crude (**8** : R₈ = CN) (687 mg, 100 %). Data: (m/z) = 305 (M+H)⁺.

A stirred solution of (**8** : R₈ = CN) (20 mg, 0.066 mmol) and triethylamine (5.75μL, 15 0.069 mmol) in DCM (0.5ml) was cooled to 0°C then a solution of dichloroacetyl chloride (6μL, 0.069 mmol) was added dropwise. The reaction was stirred for 2 hours then quenched with Na₂CO₃ solution in H₂O and the product was extracted into DCM. The organic layer was dried (Na₂SO₄) and concentrated under reduced pressure then the crude product was purified by column chromatography to afford cis-2,2-dichloro-
20 N-(8-cyano-1,2,3,4,10,14b-hexahydro-10-methyldibenzo[b,f]pyrido[1,2-*d*][1,4]diazepin-2-yl)acetamide (**9** : R₂ = COC_l₂; R₈ = CN) (20 mg, 81 %). Data: (m/z) = 415 (M+H)⁺.

25 **Example 6**, cis-N-[1,2,3,4,10,14b-hexahydro-10-methyl-N-(2,2,2-trifluoroacetyl-amino)dibenzo[b,f]pyrido[1,2-*d*][1,4]diazepin-8-yl]-2-methylpropanamide (**9** : R₂ = COCF₃; R₈ = C₄H₈NO)

To a stirred solution of (**9** : R₂ = COCF₃; R₈ = Br) (5.16 g, 11.36 mmol), Pd₂(dba)₃ (0.1 g), 2-(di-*t*-butylphosphino)biphenyl (0.2 g) and NaOBu^t (2.18 g, 22.7 mmol) in DME (150 ml) was added benzylamine (2.48 ml, 22.7 mmol) and the reaction mixture was
30 heated to 75°C and held for 20 hours. The reaction mixture was cooled to ambient temperature and was quenched by the addition of EtOAc and NaHCO₃ solution in H₂O.

The organics were separated and washed with H₂O then saturated brine, then dried (Na₂SO₄) and concentrated under reduced pressure. The crude product was purified by column chromatography to afford (**9** : R₂ = COCF₃; R₈ = C₇H₈N) (4.51 g, 83 %). Data: (m/z) = 481 (M+H)⁺.

- 5 To a stirred solution of (**9** : R₂ = COCF₃; R₈ = C₇H₈N) (2.00 g, 4.16 mmol) in EtOH (35 ml) was added 10 % Pd/C (0.2 ml, 22.7 mmol) and HCl in dioxane (1 ml) and the reaction mixture was purged three times with nitrogen. The reaction mixture was stirred for 20 hours under Hydrogen (2 bar). The reaction was quenched by the addition of EtOAc and NaHCO₃ solution in H₂O and was filtered (celite). The organics were
10 separated and washed with H₂O then saturated brine, then dried (Na₂SO₄) and concentrated under reduced pressure. The crude product was purified by column chromatography on silica to afford (**9** : R₂ = COCF₃; R₈ = NH₂) (1.39 g, 86 %). Data: (m/z) = 391 (M+H)⁺.

A stirred solution of (**9** : R₂ = COCF₃; R₈ = NH₂) (250 mg, 0.643 mmol) and
15 triethylamine (95 µL, 0.675 mmol) in DCM (7.5 ml) was cooled to 0°C and a solution of isobutyrylchloride (70 µL, 0.675 mmol) was added dropwise. The reaction was stirred at 0°C for 1 hour then quenched by the addition of EtOAc and NaHCO₃ solution in H₂O. The organics were separated and washed with H₂O then saturated brine, then dried (Na₂SO₄) and concentrated under reduced pressure. The crude product was
20 purified by column chromatography on silica to afford cis-N-[1,2,3,4,10,14b-hexahydro-10-methyl-N-(2,2,2-trifluoroacetylamino)dibenzo[b,f]pyrido[1,2-d][1,4]diazepin-8-yl]-2-methylpropanamide (**9** : R₂ = COCF₃; R₈ = C₄H₈NO) (208 mg, 70 %). Data: (m/z) = 461 (M+H)⁺.

- 25 **Example 7**, cis-N-[1,2,3,4,10,14b-hexahydro-10-methyl-N-phenyl-2-(2,2,2-trifluoroacetylamino)dibenzo[b,f]pyrido[1,2-d][1,4]diazepin-8-yl]-4-methyl-1,2,3-thiadiazole-5-carboxamide (**9** : R₂ = COCF₃; R₈ = C₄H₄N₃OS)

This compound was prepared, in an analogous manner as described in Example 6, from (**9** : R₂ = COCF₃; R₈ = NH₂), to afford, cis-N-[1,2,3,4,10,14b-hexahydro-10-methyl-N-phenyl-2-(2,2,2-trifluoroacetylamino)dibenzo[b,f]pyrido[1,2-d][1,4]diazepin-8-yl]-4-

- 20 -

methyl-1,2,3-thiadiazole-5-carboxamide (**9** : R₂ = COCF₃; R₈ = C₄H₄N₃OS) (43 %). Data: (m/z) = 517 (M+H)⁺.

Example 8, ethyl cis-1,2,3,4,10,14b-hexahydro-10-methyl-2-(2,2,2-trifluoroacetyl-amino)dibenzo[b,f]pyrido[1,2-d][1,4]diazepine-8-carboxylate (**9** : R₂ = COCF₃; R₈ = C₃H₅O₂)

A stirred solution of (**9** : R₂ = COCF₃; R₈ = Br) (500 mg, 1.10 mmol) in dry THF (10 ml) was cooled to -75°C and n-BuLi (1.44 ml 2.10 mmol) was added dropwise. After 5 minutes ethyl chloroformate (525 µL, 5.50 mmol) was added dropwise and the reaction was stirred at -75°C for 1.5 hours. The reaction was quenched by dropwise addition of H₂O and the product was extracted into EtOAc. The organic layer was dried (Na₂SO₄) and concentrated under reduced pressure. The crude product was purified by column chromatography on silica to afford ethyl cis-1,2,3,4,10,14b-hexahydro-10-methyl-2-(2,2,2-trifluoroacetylamino)dibenzo[b,f]pyrido[1,2-d][1,4]diazepine-8-carboxylate (**9** : R₂ = COCF₃; R₈ = C₃H₅O₂) (75 mg, 15 %). Data: (m/z) = 448 (M+H)⁺.

Example 9, cis-N-(7-chloro-8-cyano-1,2,3,4,10,14b-hexahydro-10-methyl-dibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl)-2,2,2-trifluoroacetamide (**9** : R₂ = COCF₃; R₇ = Cl; R₈ = CN)

This compound was prepared, in an analogous manner as described in Example 3, from (**8** : R₇ = Cl; R₈ = Br) to afford cis-N-(7-chloro-8-cyano-1,2,3,4,10,14b-hexahydro-10-methyl-dibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl)-2,2,2-trifluoroacetamide (**9** : R₂ = COCF₃; R₇ = Cl; R₈ = CN) (40 %). Data: (m/z) = 435 (M+H)⁺.

25

Example 10, cis-2,2,2-trifluoro-N-(1,2,3,4,10,14b-hexahydro-10,14-dimethyl-8-nitro-dibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl)- acetamide (**9** : R₂ = COCF₃; R₈ = NO₂; R₁₄ = CH₃)

This compound was prepared, in an analogous manner as described in Example 2, from (**9** : R₂ = COCF₃; R₁₄ = CH₃), to afford cis-2,2,2-trifluoro-N-(1,2,3,4,10,14b-hexahydro-10,14-dimethyl-8-nitro-dibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl)-acetamide (**9** : R₂ = COCF₃; R₈ = NO₂; R₁₄ = CH₃) (59 %). Data: (m/z) = 435 (M+H)⁺.

Example 11, cis-N-(14-bromo-1,2,3,4,10,14b-hexahydro-10-methyl-8-nitro-dibenzo-[*b,f*]pyrido[1,2-*d*][1,4]diazepin-2-yl)-2,2,2-trifluoroacetamide (**9** : R₂ = COCF₃; R₈ = NO₂; R₁₄ = Br)

- 5 This compound was prepared, in the analogous manner as described in Example 2, from (**9** : R₂ = COCF₃; R₁₄ = Br), to afford cis-N-(14-bromo-1,2,3,4,10,14b-hexahydro-10-methyl-8-nitro-dibenzo[*b,f*]pyrido[1,2-*d*][1,4]diazepin-2-yl)-2,2,2-trifluoroacetamide (**9** : R₂ = COCF₃; R₈ = NO₂; R₁₄ = Br) (45 %). Data: (m/z) = 500 (M+H)⁺.

10

Example 12, cis-2,2,2-trifluoro-N-[1,2,3,4,10,14b-hexahydro-10-methyl-8-nitro-14-(pyridine-2-yl)-dibenzo[*b,f*]pyrido[1,2-*d*][1,4]diazepin-2-yl]acetamide (**9** : R₂ = COCF₃; R₈ = NO₂; R₁₄ = 2-C₅H₄N)

- To a stirred solution of (**9** : R₂ = COCF₃; R₈ = NO₂; R₁₄ = Br) (40 mg, 0.080 mmol) in 15 toluene (3 ml) was charged PdCl₂(PPh₃)₂ (3.5 mg, 0.005 mmol), copper iodide (8.0 mg, 0.005 mmol), caesium fluoride (24 mg, 0.160 mmol) and 2-(tributylstannylyl)pyridine (44 mg, 0.120 mmol). The reaction mixture was heated to 120°C and held for 24 hours. The reaction was quenched with NaHCO₃ solution in H₂O and the product was extracted into EtOAc. The organics were washed with H₂O then saturated brine, then 20 dried (Na₂SO₄) and concentrated under reduced pressure. The crude product was purified by column chromatography on silica to afford cis-2,2,2-trifluoro-N-[1,2,3,4,10,14b-hexahydro-10-methyl-8-nitro-14-(pyridine-2-yl)-dibenzo[*b,f*]pyrido[1,2-*d*][1,4]diazepin-2-yl]acetamide (**9** : R₂ = COCF₃; R₈ = NO₂; R₁₄ = 2-C₅H₄N) (8 mg, 20 %). Data: (m/z) = 498 (M+H)⁺.

25

Example 13, cis-N-(8,14-dicyano-1,2,3,4,10,14b-hexahydro-10-methyldibenzo[*b,f*]-pyrido[1,2-*d*][1,4]diazepin-2-yl)-2,2,2-trifluoroacetamide(9, R₂ = COCF₃; R₈ = CN; R₁₄ = CN)

- This compound was prepared, in an analogous manner as described in Example 3, from 30 (**9** : R₂ = COCF₃; R₈ = Br; R₁₄ = Br), to afford cis-N-(8,14-dicyano-1,2,3,4,10,14b-hexahydro-10-methyldibenzo[*b,f*]pyrido[1,2-*d*][1,4]diazepin-2-yl)-2,2,2-trifluoroacetamide(**9** : R₂ = COCF₃; R₈ = CN; R₁₄ = CN) (74 %). Data: (m/z) = 426 (M+H)⁺.

Example 14, (2 α ,4 α ,14 $\beta\alpha$)-2,2,2-trifluoro-N-[1,2,3,4,10,14b-hexahydro-4,10-dimethyl-8-(pyridin-4-yl)dibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl]acetamide (**9** : R₂ = CO-CF₃; R₄ = CH₃; R₈ = 4-C₅H₄N)

- 5 A stirred solution of (**9** : R₂ = COCF₃; R₄ = CH₃; R₈ = Br) (405 mg, 0.865 mmol), PdCl₂(PPh₃)₂ (18.2 mg, 0.026 mmol), K₃PO₄.7H₂O (342.6 mg, 0.101 mmol), AsPh₃ (17.7 mg, 0.058 mmol) and 2,2-dimethylpropanediol cyclic ester pyridine-4-boronic acid (456 mg, 2.38 mmol) in 1:6 mixture of water:dioxane (3.5ml) was heated at 30 Watt to 150°C in the microwave for 15 minutes. The reaction was quenched with
- 10 NaHCO₃ solution in H₂O and the product was extracted into DCM. The organics were washed with water and concentrated under reduced pressure. The crude product was purified by column chromatography on silica to afford (2 α ,4 α ,14 $\beta\alpha$)-2,2,2-trifluoro-N-[1,2,3,4,10,14b-hexahydro-4,10-dimethyl-8-(pyridin-4-yl)dibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl]acetamide (**9** : R₂ = COCF₃; R₄ = CH₃; R₈ = 4-C₅H₄N)
- 15 (**9** : R₂ = COCF₃; R₄ = CH₃; R₈ = 4-C₅H₄N) (342 mg, 85 %). Data: (m/z) = 467 (M+H)⁺.

Example 15, cis-N-(1,2,3,4,10,14b-hexahydro-10-methyl-8-nitrodibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl)-2-thiophenethanamide (**9** : R₂ = COC₅H₅S; R₈ = NO₂)

- 20 This compound was prepared, in an analogous manner as described in Example 4, from (**8** : R₈ = NO₂), to cis-N-(1,2,3,4,10,14b-hexahydro-10-methyl-8-nitrodibenzo[b,f]-pyrido[1,2-d][1,4]diazepin-2-yl)-2-thiophenethanamide (**9** : R₂ = COC₅H₅S; R₈ = NO₂) (75 %). Data: (m/z) = 449 (M+H)⁺.

- 25 **Example 16,** cis-N-(7-chloro-1,2,3,4,10,14b-hexahydro-4,10-dimethylbibenzo[b,f]-pyrido[1,2-d][1,4]diazepin-2-yl)-2,2-difluoroacetamide (**9** : R₂ = COCHF₂; R₄ = CH₃; R₇ = Cl)

- This compound was prepared, in an analogous manner as described in Example 4, from (**8**, R₄ = CH₃ R₇ = Cl), to afford cis-N-(7-chloro-1,2,3,4,10,14b-hexahydro-4,10-dimethylbibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl)-2,2-difluoroacetamide (**9** : R₂ = COCHF₂; R₄ = CH₃; R₇ = Cl) (71 %). Data: (m/z) = 406 (M+H)⁺.

Example 17, cis-N-(1,2,3,4,10,14b-hexahydro-10-methyl-8-nitro-dibenzo[b,f]-pyrido[1,2-d][1,4]diazepin-2-yl)-N',N'-dimethylurea (**9** : R₂ = COC₂H₆N; R₈ = NO₂)

This compound was prepared, in an analogous manner as described in Example 5, from (**8**, R₈ = NO₂), to afford cis-N-(1,2,3,4,10,14b-hexahydro-10-methyl-8-nitro-dibenzo-

5 [b,f]pyrido[1,2-d][1,4]diazepin-2-yl)-N',N'-dimethylurea (**9** : R₂ = COC₂H₆N; R₈ = NO₂) (54 %). Data: (m/z) = 396 (M+H)⁺.

Example 18, cis-2,2,2-trifluoro-N-[1,2,3,4,10,14b-hexahydro-8-[(1-(hydroxyimino)-ethyl]-10,14-dimethyldibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl]acetamide (**9** : R₂ =

10 COCF₃; R₈ = 2-C₂H₄NO; R₁₄ = CH₃)

A solution of (**9** : R₂ = COCF₃; R₈ = C₂H₃O; R₁₄ = CH₃, Example 21) (50 mg, 0.116 mmol), hydroxylamine.HCl (12 mg, 0.174 mmol) and triethylamine (1 drop) in THF (1ml) was heated to 50°C and held for 20 hours. NaHCO₃ solution in H₂O was added and the product extracted into EtOAc. The organics were washed with H₂O, then

15 saturated brine, then dried (Na₂SO₄). The organics were concentrated under reduced pressure and the crude product was purified by column chromatography on silica to afford cis-2,2,2-trifluoro-N-[1,2,3,4,10,14b-hexahydro-8-[(1-(hydroxyimino)ethyl]-10,14-dimethyldibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl]acetamide (**9** : R₂ = CO-CF₃; R₈ = 2-C₂H₄NO; R₁₄ = CH₃) (49 mg, 94 %). Data: (m/z) = 447 (M+H)⁺.

20

Example 19, cis-N-(1,2,3,4,10,14b-hexahydro-10-methyl-8-nitro-dibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl)-furan-3-carboxamide (**9** : R₂ = COC₄H₃O; R₈ = NO₂)

This compound was prepared, in an analogous manner as described in Example 5, from (**8** : R₈ = NO₂), to afford cis-N-(1,2,3,4,10,14b-hexahydro-10-methyl-8-nitro-dibenzo-

25 [b,f]pyrido[1,2-d][1,4]diazepin-2-yl)-furan-3-carboxamide (**9** : R₂ = COC₄H₃O; R₈ = NO₂) (45 %). Data: (m/z) = 419 (M+H)⁺.

Example 20, cis-2,2,2-trifluoro-N-[1,2,3,4,10,14b-hexahydro-10-methyl-8-(pyridin-4-yl)dibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl]acetamide (**9** : R₂ = COCF₃; R₈ = 4-

30 C₅H₄N)

This compound was prepared, in an analogous manner as described in Example 5, from (**8** : R₈ = 4-C₅H₄N), to afford cis-2,2,2-trifluoro-N-[1,2,3,4,10,14b-hexahydro-10-me-

thyl-8-(pyridin-4-yl)dibenzo[*b,f*]pyrido[1,2-*d*][1,4]diazepin-2-yl]acetamide (**9** : R₂ = COCF₃; R₈ = 4-C₅H₄N) (31 %). Data: (m/z) = 481 (M+H)⁺.

- Example 21,** cis-N-(8-acetyl-1,2,3,4,10,14b-hexahydro-10,14-dimethyldibenzo[*b,f*]-5 pyrido[1,2-*d*][1,4]diazepin-2-yl)-2,2,2-trifluoroacetamide (**9** : R₂ = COCF₃; R₈ = C₂H₃O; R₁₄ = CH₃)

- This compound was prepared, in an analogous manner as described in Example 12, from (**9** : R₂ = COCF₃; R₈ = Br; R₁₄ = CH₃), to afford cis-N-(8-acetyl-1,2,3,4,10,14b-hexahydro-10,14-dimethyldibenzo[*b,f*]pyrido[1,2-*d*][1,4]diazepin-2-yl)-2,2,2-10 trifluoroacetamide (**9** : R₂ = COCF₃; R₈ = C₂H₃O; R₁₄ = CH₃) (22 %). Data: (m/z) = 432 (M+H)⁺.

Example 22, cis-N-(1,2,3,4,10,14b-hexahydro-10-methyl-8-nitrodibenzo[*b,f*]pyrido-[1,2-*d*][1,4]diazepin-2-yl)-2-(methylthio)acetamide (**9** : R₂ = COC₂H₅S; R₈ = NO₂)

- 15 This compound was prepared, in an analogous manner as described in Example 4, from (**8**, R₈ = NO₂), to afford cis-N-(1,2,3,4,10,14b-hexahydro-10-methyl-8-nitrodibenzo[*b,f*]pyrido[1,2-*d*][1,4]diazepin-2-yl)-2-(methylthio)acetamide (**9** : R₂ = COC₂H₅S; R₈ = NO₂) (25 %). Data: (m/z) = 413 (M+H)⁺.

- 20 **Example 23,** cis-2,2,2-trifluoro-N-[1,2,3,4,10,14b-hexahydro-10,14-dimethyl-8-(pyramidin-2-yl)dibenzo[*b,f*]pyrido[1,2-*d*][1,4]diazepin-2-yl]acetamide (**9** : R₂ = COCF₃; R₈ = C₄H₃N₂; R₁₄ = CH₃)

- This compound was prepared, in an analogous manner as described in Example 12, from (**9** : R₂ = COCF₃; R₈ = Br; R₁₄ = CH₃), to afford cis-2,2,2-trifluoro-N-[1,2,3,4,10,14b-hexahydro-10,14-dimethyl-8-(pyrimidin-2-yl)dibenzo[*b,f*]pyrido[1,2-25 *d*][1,4]diazepin-2-yl]acetamide (**9** : R₂ = COCF₃; R₈ = C₄H₃N₂; R₁₄ = CH₃) (14 %). Data: (m/z) = 468 (M+H)⁺.

- 30 **Example 24,** cis-N-(1,2,3,4,10,14b-hexahydro-10-methyl-8-nitrodibenzo[*b,f*]pyrido-[1,2-*d*][1,4]diazepin-2-yl)propionamide (**9**, R₂ = COC₂H₅; R₈ = NO₂)

This compound was prepared, in an analogous manner as described in Example 5, from (**8** : R₈ = NO₂), to afford cis-N-(1,2,3,4,10,14b-hexahydro-10-methyl-8-nitrodibenzo-

[*b,f*]pyrido[1,2-*d*][1,4]diazepin-2-yl)propionamide (**9**, R₂ = COC₂H₅; R₈ = NO₂) (55 %). Data: (m/z) = 381 (M+H)⁺.

Example 25, (2 α ,4 α ,14 $\beta\alpha$)-2,2,2-trifluoro-N-(8-fluoro-1,2,3,4,10,14b-hexahydro-4,10-dimethyldibenzo[*b,f*]pyrido[1,2-*d*][1,4]diazepin-2-yl)acetamide (**9** : R₂ = COCF₃; R₄ = CH₃; R₈ = F)

This compound was prepared, in an analogous manner as described in Example 1, from (**8** : R₄ = CH₃; R₈ = F), to afford (2 α ,4 α ,14 $\beta\alpha$)-2,2,2-trifluoro-N-(8-fluoro-1,2,3,4,-10,14b-hexahydro-4,10-dimethyldibenzo[*b,f*]pyrido[1,2-*d*][1,4]diazepin-2-yl)acetamide (**9** : R₂ = COCF₃; R₄ = CH₃; R₈ = F) (62 %). Data: (m/z) = 408 (M+H)⁺.

Example 26, cis-N-(1,2,3,4,10,14b-hexahydro-10-methyl-8-nitrodibenzo[*b,f*]pyrido[1,2-*d*][1,4]diazepin-2-yl)-2-methoxyacetamide (**9** : R₂ = COC₂H₅O; R₈ = NO₂)

This compound was prepared, in an analogous manner as described in Example 5, from (**8** : R₈ = NO₂), to afford , cis-N-(1,2,3,4,10,14b-hexahydro-10-methyl-8-nitrodibenzo[*b,f*]pyrido[1,2-*d*][1,4]diazepin-2-yl)-2-methoxyacetamide (**9** : R₂ = COC₂H₅O; R₈ = NO₂) (46 %). Data: (m/z) = 397 (M+H)⁺.

Example 27, cis-2,2,2-trifluoro-N-(1,2,3,4,10,14b-hexahydro-10-methyl-8-(2-methyl-2H-tetrazol-5-yl)dibenzo[*b,f*]pyrido[1,2-*d*][1,4]diazepin-2-yl)acetamide (**9** : R₂ = COCF₃; R₈ = C₂H₃N₄)

To a stirred solution of (**9** : R₂ = COCF₃; R₈ = CN, Example 3) (100 mg, 0.250 mmol) in DMF (2.5 ml) was charged sodium azide (195 mg, 3.00 mmol) and ammonium chloride (160 mg 3.00 mmol). The reaction mixture was heated at 20 Watt to 150°C in the microwave and held for 5 minutes. An acid-base extraction was performed and the product extracted into EtOAc. The organic layer was washed with water, dried (Na₂SO₄) and concentrated under reduced pressure to yield a solid (48 mg, 43 %). The crude product (39 mg, 0.088 mmol) was dissolved in 1:1 mixture of DMF : acetone (5 ml) then sodium bicarbonate (11.1 mg, 0.132 mmol) and methyl iodide (54.7 mg, 0.880 mmol) were added and the reaction mixture was stirred at ambient temperature for 24 hours. EtOAc was then added and the reaction mixture was washed with water, dried (Na₂SO₄) then concentrated under reduced pressure. The crude product was purified by

column chromatography over silica to afford cis-2,2,2-trifluoro-N-(1,2,3,4,10,14b-hexahydro-10-methyl-8-(2-methyl-2H-tetrazol-5-yl)dibenzo[*b,f*]pyrido[1,2-*d*][1,4]diazepin-2-yl)acetamide (**9** : R₂ = COCF₃; R₈ = C₂H₃N₄) (7 mg, 17 %). Data: (m/z) = 458 (M+H)⁺.

5

Example 28, cis-2,2,2-trifluoro-N-(1,2,3,4,10,14b-hexahydro-8-[(hydroxyimino)-ethyl]-10-methyldibenzo[*b,f*]pyrido[1,2-*d*][1,4]diazepin-2-yl)acetamide (**9** : R₂ = COCF₃; R₈ = C₂H₄NO)

This compound was prepared, in an analogous manner as described in Example 18, from (**9** : R₂ = COCF₃; R₈ = COCH₃), to afford cis-2,2,2-trifluoro-N-(1,2,3,4,10,14b-hexahydro-8-[(hydroxyimino)ethyl]-10-methyldibenzo[*b,f*]pyrido[1,2-*d*][1,4]diazepin-2-yl)acetamide (**9** : R₂ = COCF₃; R₈ = C₂H₄NO) (55 %). Data: (m/z) = 433 (M+H)⁺.

Example 29, (2 α ,4 α ,14 $\beta\alpha$)-N-(7-chloro-1,2,3,4,10,14b-hexahydro-4,10-dimethyl-dibenzo[*b,f*]pyrido[1,2-*d*][1,4]diazepin-2-yl)-3,5-dimethylisoxazole-4-carboxamide (**9** : R₂ = COC₅H₆NO; R₄ = CH₃; R₇ = Cl)

This compound was prepared, in an analogous manner as described in Example 5, from (**8** : R₄ = CH₃; R₇ = Cl), to afford (2 α ,4 α ,14 $\beta\alpha$)-N-(7-chloro-1,2,3,4,10,14b-hexahydro-4,10-dimethyl-dibenzo[*b,f*]pyrido[1,2-*d*][1,4]diazepin-2-yl)-3,5-dimethylisoxazole-4-carboxamide (**9** : R₂ = COC₅H₆NO; R₄ = CH₃; R₇ = Cl) (15 %). Data: (m/z) = 451 (M+H)⁺.

Example 30, cis-N-(1,2,3,4,10,14b-hexahydro-10-methyl-8-nitrodibenzo[*b,f*]pyrido[1,2-*d*][1,4]diazepin-2-yl)-5-methylisoxazole-4-carboxamide (**9** : R₂ = COC₄H₄NO; R₈ = NO₂)

This compound was prepared, in an analogous manner as described in Example 4, from (**8**, R₈ = NO₂), to afford cis-N-(1,2,3,4,10,14b-hexahydro-10-methyl-8-nitrodibenzo[*b,f*]pyrido[1,2-*d*][1,4]diazepin-2-yl)-5-methylisoxazole-4-carboxamide (**9** : R₂ = CO-C₄H₄NO; R₈ = NO₂) (27 %). Data: (m/z) = 434 (M+H)⁺.

Example 31, cis-N-(1,2,3,4,10,14b-hexahydro-10-methyl-8-nitrodibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl)-4-methyl-1,2,3-thiadiazole-5-carboxamide (**9** : R₂ = COC₃H₃N₂S; R₈ = NO₂)

This compound was prepared, in an analogous manner as described in Example 5, (**8** : R₈ = NO₂), to afford cis-N-(1,2,3,4,10,14b-hexahydro-10-methyl-8-nitrodibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl)-4-methyl-1,2,3-thiadiazole-5-carboxamide (**9** : R₂ = COC₃H₃N₂S; R₈ = NO₂) (72 %). Data: (m/z) = 451 (M+H)⁺.

Example 32, cis-N-(8-(6-cyanopyridin-2-yl)-1,2,3,4,10,14b-hexahydro-10-methyl-10 dibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl)-2,2,2-trifluoroacetamide (**9** : R₂ = COCF₃; R₈ = C₆H₃N₂)

This compound was prepared, in an analogous manner as described in Example 12, (**9** : R₂ = COCF₃; R₈ = Br), to afford cis-N-(8-(6-cyanopyridin-2-yl)-1,2,3,4,10,14b-hexahydro-10-methyl-dibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl)-2,2,2-trifluoroacetamide (**9** : R₂ = COCF₃; R₈ = C₆H₃N₂) (58 %). Data: (m/z) = 478 (M+H)⁺.

Example 33 cis-N-[8-(5-ethyl-1,2,4-oxadiazol-3-yl)-1,2,3,4,10,14b-hexahydro-10-methyldibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl]-2,2,2-trifluoroacetamide (**9** : R₂ = COCF₃; R₈ = C₄H₅N₂O)

To a stirred solution of (**9** : R₂ = COCF₃; R₈ = CN) (391 mg, 0.980 mmol) and triethylamine (212 µL, 1.51 mmol) in ethanol (5 ml) was charged hydroxylamine hydrochloride (102 mg, 1.47 mmol) and the reaction mixture was heated to 80°C and held for 24 hours. The reaction mixture was reduced by rotary evaporation to yield an oil which was dissolved in DCM and washed with H₂O. The organics were then dried (Na₂SO₄) and concentrated under reduced pressure to yield an oil (420 mg, 100%). The crude product (31 mg, 0.072 mmol) was dissolved in toluene (1 ml) then pyridine (23 µL, 0.280 mmol) and propionyl chloride (12.5 µL, 0.140 mmol) were added and the reaction mixture was heated at 120°C for 2 hours. The reaction mixture was washed with water, dried (Na₂SO₄) then concentrated under reduced pressure. The crude product was purified by reverse phase HPLC to afford cis-N-[8-(5-ethyl-1,2,4-oxadiazol-3-yl)-1,2,3,4,10,14b-hexahydro-10-methyldibenzo[b,f]pyrido[1,2-d][1,4]dia-

zepin-2-yl]-2,2,2-trifluoroacetamide (**9** : R₂ = COCF₃; R₈ = C₄H₅N₂O) (6 mg, 18 %). Data: (m/z) = 472 (M+H)⁺.

- Example 34,** cis-N-(1,2,3,4,10,14b-hexahydro-10-methyl-8-nitrodibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl)-2-hydroxypropanamide (**9** : R₂ = COC₂H₅O; R₈ = NO₂)
- This compound was prepared, in an analogous manner as described in Example 5, from (**8** : R₈ = NO₂). The isolated compound was then taken up in EtOH and an 8% solution of NaOH was added. The reaction mixture was stirred at ambient temperature for 2 hours. Most of the EtOH was removed by under reduced pressure. H₂O was then added and the product was extracted into DCM. The organics were then washed with saturated brine and dried (Na₂SO₄). The organics were concentrated under reduced pressure and the crude product was purified by column chromatography over silica to afford cis-N-(1,2,3,4,10,14b-hexahydro-10-methyl-8-nitrodibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl)-2-hydroxypropanamide (**9** : R₂ = COC₂H₅O; R₈ = NO₂) (49 %).
- Data: (m/z) = 397 (M+H)⁺.

Example 35, cis-N-(9-chloro-8-cyano-1,2,3,4,10,14b-hexahydro-10-methyldibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl)-2,2,2-trifluoroacetamide (**9**, R₂ = COCF₃; R₈ = CN; R₉ = Cl)

- This compound was prepared, in an analogous manner as described in Example 3, from (**9** : R₂ = COCF₃; R₈ = Br; R₉ = Cl), to afford cis-N-(9-chloro-8-cyano-1,2,3,4,10,14b-hexahydro-10-methyldibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl)-2,2,2-trifluoroacetamide (**9**, R₂ = COCF₃ R₈ = CN R₉ = Cl) (60 %). Data: (m/z) = 435 (M+H)⁺.

25

Example 36, cis-N-(5-methoxypyridin-3-yl)-1,2,3,4,10,14b-hexahydro-10-methyl-2-(2,2,2-trifluoroacetylarnino)dibenzo[b,f]pyrido[1,2-d][1,4]diazepine-8-carboxamide (**9** : R₂ = COCF₃; R₈ = C₇N₇N₂O₂)

- To a stirred solution of (**9** : R₂ = COCF₃; R₈ = CHO₂, Example 4) (20 mg, 0.048 mmol) in DCM (0.5 ml) and DMF (2 drops) was added a solution of oxalyl chloride (6.8 μL, 0.078 mmol) in DCM (0.5 ml). The reaction mixture was stirred for 1 hour at room temperature. The solvent was then removed under reduced pressure and the resulting

oil was dissolved in THF (0.5 ml). Triethylamine (7.3 μ L, 0.052 mmol) was then added and the reaction mixture was cooled to 0°C. A solution of 5-amino-2-methoxypyridine (6.5 mg, 0.052 mmol) in THF (0.5 ml) was then added and the reaction mixture was allowed to stir at ambient temperature for 20 hours. The reaction was quenched by addition of NaHCO₃ solution in H₂O and the product was extracted into EtOAc, dried (Na₂SO₄) and concentrated under reduced pressure. The crude product was purified by column chromatography on silica to afford cis-N-(5-methoxypyridin-3-yl)-1,2,3,4,10,14b-hexahydro-10-methyl-2-(2,2,2-trifluoroacetylamino)dibenzo[b,f]pyrido[1,2-d][1,4]diazepine-8-carboxamide (**9** : R₂ = COCF₃; R₈ = C₇N₇N₂O₂) (39 %). Data: 10 (m/z) = 526 (M+H)⁺.

- Example 37,** cis-1,2,3,4,10,14b-hexahydro-10,14-dimethyl-2-(2,2,2-trifluoroacetylamino)dibenzo[b,f]pyrido[1,2-d][1,4]diazepine-8-carboxamide (**9** : R₂ = COCF₃; R₈ = CH₂NO; R₁₄ = CH₃)
- 15 This compound was prepared, in an analogous manner as described in Example 1, from (**8** : R₈ = CH₂NO; R₁₄ = CH₃), to afford cis-1,2,3,4,10,14b-hexahydro-10,14-dimethyl-2-(2,2,2-trifluoroacetylamino)dibenzo[b,f]pyrido[1,2-d][1,4]diazepine-8-carboxamide (**9** : R₂ = COCF₃; R₈ = CH₂NO; R₁₄ = CH₃) (19 %). Data: (m/z) = 433 (M+H)⁺.
- 20 **Example 38,** cis-2,2,2-trifluoro-N-[1,2,3,4,10,14b-hexahydro-8-(2-hydroxyacetyl)-10,14-dimethylbibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl]acetamide (**9** : R₂ = CO-CF₃; R₈ = C₂H₃O₂)
- To a stirred solution of (**9** : 2-CF₃; 8-C₂H₃O) (660 mg, 1.58 mmol) in dioxane (20 ml) was charged a solution of bromine (68.4 μ L, 1.58 mmol) in Et₂O (5 ml) was added 25 dropwise. The reaction mixture was heated to 40°C for 30 hours. The reaction was quenched by addition of NaHCO₃ solution in H₂O and the product was extracted into EtOAc, dried (Na₂SO₄) and concentrated under reduced pressure. The crude product was purified by column chromatography on silica to afford (**9** : R₂ = COCF₃; R₈ = C₂H₂BrO) (350 mg, 45 %). The product (**9** : R₂ = COCF₃; R₈ = C₂H₂BrO) (170 mg, 30 0.343 mmol) was then dissolved in EtOH/H₂O (85:15) (20 ml) and sodium formate (140 mg, 2.058 mmol) was added portionwise. The reaction mixture was stirred at ambient temperature for 20 hours. The reaction was quenched by addition of NaHCO₃

solution in H₂O and the product was extracted into EtOAc, dried (Na₂SO₄) and concentrated under reduced pressure. The crude product was purified by reverse phase HPLC to afford cis-2,2,2-trifluoro-N-[1,2,3,4,10,14b-hexahydro-8-(2-hydroxyacetyl)-10,14-dimethylbibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl]acetamide (**9** : R₂ = CO-5 CF₃; R₈ = C₂H₃O₂) (46 mg, 31 %). Data: (m/z) = 434 (M+H)⁺.

Example 39, cis-1,2,3,4,10,14b-hexahydro-10-methyl-N-propyl-2-(2,2,2-trifluoroacetylamino)dibenzo[b,f]pyrido[1,2-d][1,4]diazepine-8-carboxamide (**9** : R₂ = COCF₃; R₈ = C₄H₈NO)

10 This compound was prepared, in an analogous manner as described in Example 36, from (**9** : R₂ = COCF₃; R₈ = CHO₂, Example 4), to afford cis-1,2,3,4,10,14b-hexahydro-10-methyl-N-propyl-2-(2,2,2-trifluoroacetylamino)dibenzo[b,f]pyrido[1,2-d][1,-4]diazepine-8-carboxamide (**9** : R₂ = COCF₃; R₈ = C₄H₈NO) (27 %). Data: (m/z) = 461 (M+H)⁺.

15

Example 40, cis-2,2,2-trifluoro-N-[1,2,3,4,10,14b-hexahydro-10-methyl-8-(5-methoxymethyl-1,2,4-oxadiazol-3-yl)dibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl]acetamide (**9** : R₂ = COCF₃; R₈ = C₄H₅N₂O₂)

To a stirred solution of (**9** : R₂ = COCF₃; R₈ = CN) (391 mg, 0.980 mmol) and triethylamine (212 µL, 1.51 mmol) in ethanol (5 ml) was charged hydroxylamine hydrochloride (102 mg, 1.47 mmol) and the reaction mixture was heated to 80°C and held for 24 hours. The reaction mixture was reduced by rotary evaporation to yield an oil which was dissolved in DCM and washed with H₂O. The organics were then dried (Na₂SO₄) and concentrated under reduced pressure to yield an oil (420 mg, 100%). The 20 crude product (60 mg, 0.140 mmol) was dissolved in pyridine (1 ml) and methoxyacetyl chloride (25.5 µL, 0.280 mmol) was added then the reaction mixture was heated at reflux for 3 hours. The reaction mixture was washed with water, dried (Na₂SO₄) then concentrated under reduced pressure. The crude product was purified by reverse phase HPLC to afford cis-2,2,2-trifluoro-N-[1,2,3,4,10,14b-hexahydro-10-25 methyl-8-(5-methoxymethyl-1,2,4-oxadiazol-3-yl)dibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl]acetamide (**9** : R₂ = COCF₃; R₈ = C₄H₅N₂O₂) (12 mg, 18%). Data: (m/z) = 488 (M+H)⁺.

Example 41, cis-2,2,2-trifluoro-N-[1,2,3,4,10,14b-hexahydro-10-methyl-8-(3-methoxy-pyridin-5-yl)dibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl]acetamide (**9** : R₂ = COCF₃; R₈ = C₆H₆NO)

This compound was prepared, in an analogous manner as described for 12, from (**9** : R₂ = COCF₃; R₈ = Br), to afford cis-2,2,2-trifluoro-N-[1,2,3,4,10,14b-hexahydro-10-methyl-8-(3-methoxy-pyridine-5-yl)dibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl]acetamide (**9** : R₂ = COCF₃; R₈ = C₆H₆NO) (54 %). Data: (m/z) = 483 (M+H)⁺.

Example 42, cis-N-(12-cyano-1,2,3,4,10,14b-hexahydro-10-methyl-8-nitro-dibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl)-2,2,2-trifluoroacetamide (**9** : R₂ = COCF₃; R₈ = NO₂; R₁₂ = CN)

This compound was prepared, in an analogous manner as described in Example 2, from (**9** : R₂ = COCF₃; R₁₂ = CN), to afford cis-N-(12-cyano-1,2,3,4,10,14b-hexahydro-10-methyl-8-nitro-dibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl)-2,2,2-trifluoroacetamide (**9** : R₂ = COCF₃; R₈ = NO₂; R₁₂ = CN) (10 %). Data: (m/z) = 446 (M+H)⁺.

Example 43, cis-N-(8,13-dibromo-1,2,3,4,10,14b-hexahydro-10,14-dimethyldibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl)-2,2,2-trifluoroacetamide (**9** : R₂ = COCF₃; R₈ = Br; R₁₃ = Br; R₁₄ = CN)

This compound was prepared, in an analogous manner as described in Example 3, from (**9** : R₂ = COCF₃; R₁₄ = CN) to afford cis-N-(8,13-dibromo-1,2,3,4,10,14b-hexahydro-10,14-dimethyldibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl)-2,2,2-trifluoroacetamide (**9** : R₂ = COCF₃; R₈ = Br; R₁₃ = Br; R₁₄ = CN) (33 %). Data: (m/z) = 548 (M+H)⁺.

Example 44, cis-N-[1,2,3,4,10,14b-hexahydro-10-methyl-8-(pyridin-4-yl)-dibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl]-methanesulfonamide (**9** : R₂ = S(O)₂CH₃; R₈ = 4-C₅H₄N)

To a stirred solution of (**8** ; R₈ = 4-C₅H₄N) (200 mg, 0.54 mmol) in dichloromethane (10 ml) was added triethylamine (81 µL) and methanesulphonylchloride (45 µL), maintaining the temperature at 0°C during the course of the addition. The reaction mixture was then stirred 2hours at ambient temperature. The reaction was quenched with water and washed with saturated aqueous sodium hydrogen carbonate, brine and

dried over magnesium sulphate. The reaction mixture was concentrated under reduced pressure and the crude product was purified by column chromatography on silica to afford cis-N-[1,2,3,4,10,14b-hexahydro-10-methyl-8-(pyridin-4-yl)-dibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl]-methanesulfonamide (**9** : R₂ = S(O)₂CH₃; R₈ = 4-C₅H₄N) 5 (160 mg, 66 %). Data: (m/z) = 449 (M+H)⁺.

Example 45, cis-N-(1,2,3,4,10,14b-hexahydro-10-methyl-8-cyanodibenzo[b,f]pyrido[1,2-d][1,4]-diazepin-2-yl)-N'methyl-N'methoxyurea (**9**:R₂ = CO N(Me)OMe, R₈ = CN)

10 To a stirred solution of cis-N-(8-cyano-1,2,3,4,10,14b-hexahydro-10-methyldibenzo-[b,f]pyrido[1,2-d][1,4]diazepin-2-yl)-2,2,2-trifluoroacetamide (**9** : R₂ = COCF₃; R₈ = CN) (4.36 g, 10.9 mmol) in EtOH (72 ml) was added 2N NaOH (19.2 ml). The reaction mixture was stirred overnight at ambient temperature, then the reaction mixture was poured into water and extracted with EtOAc. The organic layer was 15 washed with H₂O, then saturated brine, then dried (Na₂SO₄) and concentrated under reduced pressure to afford crude (**8**: R₈ = CN) (3.04 g, 92 %). Data: (m/z) = 305 (M+H)⁺.

To a stirred solution of (**8**: R₈ = CN) (200 mg, 0.658 mmol) in EtOAc (8 ml) was added a catalytic amount of activated charcoal and trichloromethylchloroformate (94.8 20 μl, 0.197 mmol). The reaction mixture was stirred at reflux for 2 hours. The reaction mixture was filtered over dicalite and concentrated under reduced pressure to afford crude (**8**: isocyanate on position 2 (NCO), R₈ = CN) (217 mg, 100 %). Data: (m/z) = 331 (M+H)⁺.

To a stirred solution of (**8**: (NHR₂ = NCO, R₈ = CN) (54 mg, 0.164 mmol) in EtOAc (10 ml) was added a solution of N,O-dimethylhydroxylamine hydrochloride (80 mg, 0.197 mmol) with triethylamine (23.7 μl, 0.197 mmol) in EtOAc (5 ml). The reaction mixture was stirred at 50 °C for 2 days and then poured in water and extracted with EtOAc. The organic layer was washed with H₂O and saturated brine, then dried (Na₂SO₄) and concentrated under reduced pressure to afford after purification (**9**: R₂ = 25 CON(Me)OMe, R₈ = CN) (5.9 mg, 9.2 %). Data: (m/z) = 392 (M+H)⁺.

Example 46 Glucocorticoid receptor binding activity

The affinity of compounds was tested using a Glucocorticoid Receptor Competitor Assay kit (PanVera[®]). Components of the kit were thawed from - 80°C on ice (Fluormone GS1, recombinant human-GR (GR)) or at room temperature (GR screening buffer, stabilising peptide and DTT). 10mM test compounds were manually diluted to 20µM then serially diluted to a final concentration range of 10µM to 0.1nM using the BioMek 2000 (Beckman-Coulter) into a black walled 384 welled plate (Matrix technologies). In the following order: fluormone GS1 (1nM final concentration) is added to all wells excluding the buffer control wells, GR (4nM final concentration) is added to all wells except minimum and buffer control wells, cortisol (10µM final concentration) is added to fluormone GS1 control wells only, buffer is added to all wells to a final volume of 40µl. The plate is covered and incubated at room temperature with agitation for 90 minutes. Readings were taken using the Analyst (LJL) in fluorescence polarisation reading mode. The MilliP ratio is calculated from cps readings obtained in parallel and perpendicular mode. The percent effect of the bound ligand is calculated at each concentration and the dose response curves plotted allowing the EC₅₀ to be calculated. This is compared to the known standard (11 β ,17 β)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one (CAS No. 189035-07-2), EC₅₀ = 10⁻⁸ M). All compounds exemplified have binding activities < 2 x 10⁻⁸ M.

Example 47 Functional responses in vitro

To quantify the ability of compounds to inhibit inflammatory gene expression in vitro, responses of compounds were evaluated in the human cell line U2OS that was stably transfected with human recombinant GR DNA. U2OS cells were stimulated with TNF α and IFN γ which leads to the secretion of MCP-1 in the supernatant. Secretion of MCP-1 was quantified indirectly by the use of two anti-human-MCP-1 antibodies, one labeled with the fluorescent donor Europium, the second one labeled with the fluorescent acceptor Allophycocyanin (APC). Secretion of MCP-1 in supernatant is

quantified by measuring the emission wavelength of APC (665 nm) when Europium is excited at 340 nm. The ability of compounds (prednisolone or compounds according to formula I) to inhibit MCP-1 expression was quantified and EC₅₀ values were calculated. Examples 1, 2, 10, 11 and 14-24 showed an EC₅₀ of 0.2-2 nM whereas the
5 value found for prednisolone was 2 nM.

Example 48 Anti-inflammatory activity in vivo


The potency of compounds to inhibit inflammation was quantified in a model in which mice were treated with lipopolysaccharide (LPS). Anti-inflammatory effects were
10 quantified as inhibition of LPS-induced TNF α (S.R. Hyde & R.E. McCallum, Infection & Immunity, 60; 976-982 (1992)). Mice were treated i.p. with 0.5 mg/kg LPS. Compounds (prednisolone or compounds according to formula I) were dosed systemically by either oral or subcutaneous administration at 1 hour before the induction with LPS. 1½ hours after LPS induction, serum was collected and mice were
15 sacrificed. TNF α levels in serum were quantified using a commercially available Elisa-kit according to the descriptions of the supplier. Both prednisolone as well as compounds according to examples 2-7, 9 and 31, dose-dependently inhibited TNF α (ED₅₀ : 0.5-20 mg/kg as compared to 0.5 for prednisolone).

20 **Example 49 Anti-arthritis activity in vivo**

The ability of compounds to inhibit arthritis was tested in a Collagen type II-Induced Arthritis model in mice (D.E. Trentham et al. J Exp Med 146; 857-868 (1977)). In this model male Dba/1 mice were immunized and boosted (after 3 weeks) with Collagen. Arthritis is scored as swelling of paws. Mice that develop arthritis are treated for 3
25 weeks either with prednisolone or compounds according to formula I, either orally or subcutaneously (the therapeutic model). Alternatively, treatment with prednisolone or compounds according to formula I, either orally or subcutaneously starts before the onset of arthritis (the semi-therapeutic model). In both the therapeutic as well as the semi-therapeutic model, further development of arthritis is scored as paw swelling 3
30 times a week. After 3 weeks, mice are sacrificed. Potency of compounds to inhibit arthritis is quantified as the ability to inhibit paw swelling. Both prednisolone as well as the examples (examples 2-5) tested (at a dose of 10 or 20 mg/kg) are able to significantly inhibit arthritis.

Claims

1. A compound according to general formula I:



Formula I

5

or a pharmaceutically acceptable salt thereof, wherein

R_1 is H or (1-4C)alkyl;

R_2 is $-C(O)R_{15}$ or $-S(O)_2R_{15}$;

R_3 is H, (1-4C)alkyl or -OR₁₆;

10 R₄ is H, (1-4C)alkyl or -OR₁₆;

R_6 is H, -C(H)NOR₁₆;

R_7 is H, halogen or cyano;

or R₇ is (1-6C)alkyl, (2-6C)alkenyl or (2-6C)alkynyl, all three optionally substituted with OH, halogen or NH₂;

or R₇ is -C(H)NOR₁₆, -OR₁₆, -C(O)OR₁₆ or -C(O)R₁₆;

R₈ is H, cyano, halogen or nitro;

or R₈ is (1-6C) alkyl, (2-6C) alkenyl, (2-6C) alkynyl or -O(1-6C)alkyl, all optionally substituted with amino, hydroxyl or halogen;

or R₈ is (hetero)aryl, optionally substitut-

4C)alkoxy or (1-4C)alkoxy(1-4C)alkyl;

or R₈ is -C(H)NOR₁₆, -C(O)NHR₁₇, -C

NHS(O)₂R₂₁ or -C(1-4C)alkylNOR₂₁;

R₉ is H, halogen, cyano

R_{10} is H e

R₁₁ is H;

- R₁₃ is H, (1-4C)alkyl, halogen or formyl;
- R₁₄ is H, halogen, cyano, (1-4C)alkyl, (2-6C)alkenyl, C(O)R₂₁ or (hetero)aryl;
- R₁₅ is H;
- or R₁₅ is (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, -O(2-6C)alkyl, -O(2-6C)alkenyl or -O(2-6C)alkynyl, all optionally substituted with one or more OH, halogen, cyano or (hetero)aryl;
- 5 or R₁₅ is (hetero)aryl, optionally substituted with (1-4C)alkyl, halogen, cyano, nitro or amino;
- or R₁₅ is NH₂, (di)(1-4C)alkylamino, (1-4C)alkyl(1-4C)alkoxyamine, (1-4C)alkylthio(1-4C)alkyl or (1-4C)alkoxy(1-4C)alkyl;
- 10 each R₁₆ independently is H, (1-6C)alkyl, (2-6C)alkenyl or (2-6C)alkynyl;
- R₁₇ is H, (1-4C)alkoxy or (3-6C)cycloalkyl;
- or R₁₇ is (1-6C)alkyl, optionally substituted with halogen;
- or R₁₇ is (hetero)aryl, optionally substituted with halogen, (1-4C)alkyl or (1-4C)alkoxy.
- 15 R₁₈ is H, NH₂, -C(O)R₂₁ or -S(1-4C)alkyl;
- or R₁₈ is 1-4C)alkyl, optionally substituted with OH, halogen or cyano;
- R₁₉ is H or (1-6C)alkyl, optionally substituted with OH or halogen, and
- R₂₀ is H, (1-6C)alkyl or (2-6C)alkenyl, both optionally substituted with halogen,
- 20 -O(1-6C)alkyl, or (hetero)aryl, optionally substituted with (1-4C)alkyl or halogen;
- or R₂₀ is (3-6C)cycloalkyl (1-6C)alkoxy; (1-6C)alkenyloxy or (hetero)aryl, optionally substituted with (1-4C)alkyl), NH₂, -NH(1-6C)alkyl or -NH(hetero)aryl;
- each R₂₁ independently is H or (1-6C)alkyl.
- 25 2. The compound according to claim 1 wherein R₇ is H or halogen or OR₁₆.
3. The compound according to claims 1-2 wherein R₇ is H.
4. The compound according to claims 1-3 wherein R₁₀ is methyl.
5. The compound according to claims 1-4 wherein each R₁₆ is independently H or (1-6C)alkyl.
- 30 6. The compounds according to claims 1-5 wherein R₂ is C(O)R₁₅

7. The compound according to claims 1-6 wherein R₁₅ is (1-4C)alkyl, optionally substituted with halogen.
8. The compound according to claim 7 wherein R₁₅ is trifluoromethyl.
9. The compound according to claims 1-8 wherein each R₂₁ is independently (1-4C)alkyl.
10. The compound according to claims 1-8 wherein R₈ is H, halogen, cyano, nitro, C(O)R₁₈, or -NHC(O)R₂₀;
or R₈ is (hetero)aryl, optionally substituted with cyano, (1-4C)alkyl, (1-4C)alkoxy, (1-4C)alkoxy(1-4C)alkyl or (hetero)aryl).
11. The compound according to claims 10 wherein R₈ is H, cyano, pyridyl or nitro.
12. The compound of anyone of claims 1-10 for use in therapy.
13. Use of the compound of claims 1-10 or a pharmaceutically acceptable salt or solvate thereof for the manufacture of a medicament for patients in need of modulating the glucocorticoid receptor.
14. Use of the compound of claims 1-10 or a pharmaceutically acceptable salt or solvate thereof for the manufacture of a medicament to treat immunological and inflammatory diseases.
15. Use of the compound of claims 1-10 or a pharmaceutically acceptable salt or solvate thereof for the manufacture of a medicament in the field of rheumatology, hematology, pulmology, dermatology, gastro-enterology, endocrinology, neurology or nephrology.

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2006/050906

A. CLASSIFICATION OF SUBJECT MATTER INV. C07D471/04 A61K31/551 A61P29/00		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) C07D		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, WPI Data, BEILSTEIN Data, CHEM ABS Data		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 03/084963 A (AKZO NOBEL N.V; HERMKENS, PEDRO, HAROLD, HAN; LUCAS, HANS; DOLS, PAUL,) 16 October 2003 (2003-10-16) page 1; claim 1 ----- US 4 054 572 A (VAN DER BURG ET AL) 18 October 1977 (1977-10-18) column 9, line 52 - line 62; claim 1 ----- WO 03/104195 A (BOEHRINGER INGELHEIM PHARMACEUTICALS, INC) 18 December 2003 (2003-12-18) page 1, line 2 - line 5; claim 1 -----	1-15 1-15 1-15
<input type="checkbox"/> Further documents are listed in the continuation of Box C.		<input checked="" type="checkbox"/> See patent family annex.
<p>* Special categories of cited documents :</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p>		
Date of the actual completion of the international search	Date of mailing of the international search report	
20 April 2006	27/04/2006	
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer Seelmann, I	

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2006/050906

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO 03084963	A	16-10-2003	AU	2003224161 A1	20-10-2003
			BR	0308890 A	11-01-2005
			CA	2480940 A1	16-10-2003
			CN	1649879 A	03-08-2005
			HR	20040913 A2	31-08-2005
			JP	2005528382 T	22-09-2005
			MX	PA04009709 A	13-12-2004
			US	2005171087 A1	04-08-2005
US 4054572	A	18-10-1977	NONE		
WO 03104195	A	18-12-2003	AU	2003249669 A1	22-12-2003
			CA	2486491 A1	18-12-2003
			EP	1513810 A1	16-03-2005
			JP	2005529165 T	29-09-2005